Navigation Links
Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
Date:10/18/2010

ight dose of Intermezzo®.  A secondary analysis that evaluated mean differences in SDLP between Intermezzo® and placebo administered three hours prior to driving showed a difference of 1.5 cm, which was statistically significant.

Driving data: 9 hours after dosing zopiclone at bedtime, the active controlZopiclone was studied to establish that the test design was capable of detecting driving impairment.  Zopiclone worked as expected, confirming the ability of the study to detect such impairment. The symmetry analysis showed statistically significant drug effect on driving performance in healthy subjects who began driving an automobile nine hours after receiving zopiclone at bedtime.  The mean difference in SDLP between zopiclone and placebo administered nine hours prior to driving showed a difference of 2.5 cm, which was statistically significant.

Three drives were terminated prematurely during the study due to excessive sleepiness.  One subject failed to complete two drives, one on the zopiclone treatment arm, the active control in the study, and the other on the Intermezzo® 3-hour treatment arm. A second subject failed to complete the drive in the zopiclone treatment arm.

Glenn A. Oclassen, Transcept President and Chief Executive Officer, said, "The findings from this highway driving study reinforce our belief that Intermezzo® has the potential to be the first FDA approved sleep medication for use as needed when a  middle of the night awakening is followed by difficulty returning to sleep.  If approved by the FDA, these results will further differentiate Intermezzo® from other sleep aids by providing physicians and their patients with important safety information from what we believe to be the largest highway driving study of its kind. This study is a central component of our broader resubmission strategy to address the concerns expressed by the FDA in
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at BIO Investor Forum
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
7. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
8. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
10. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
11. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...  Levi & Korsinsky, LLP is investigating Alexza Pharmaceuticals ... breaches of fiduciary duty by the board of directors ... click here: http://zlk.9nl.com/alexza-pharmaceuticals-alxa . There is no cost ... common stock in Alexza Pharmaceuticals Inc. and wish to ... either via email at ek@zlk.com or ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... OTEMR, Inc. , ONETOUCH EMR, 2.0 has achieved ONC ... the software is capable of supporting eligible providers with ... measures required to qualify for funding under the American ... certified on July 14, 2014 by ICSA Labs ... (ONC-ACB) and is compliant in accordance with applicable criteria ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
(Date:9/18/2014)... 18, 2014 INDIGO Biosciences, a leading ... that it has released a new Human Estrogen-related Orphan ... kits are available. , ERR? is naturally expressed in ... in a variety of other tissue types, including kidney, ... a potential target for anti-obesity therapeutics. Cross-talk between ...
(Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
(Date:9/18/2014)... September 18, 2014 Dentists from ... of highly acclaimed Oxnard All-on-4™ dental implants ... a prosthodontist from the Anacapa Dental Art Institute ... the Canadian Academy of Restorative Dentistry and Prosthodontics ... Reshad’s presentation, “Resection Versus Augmentation: Esthetic Implant Supported ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... Fla (PRWEB) September 18, 2014 According to ... suffer from eczema, with many of them being children. In ... first diagnosed as babies and children. The millions of children ... can be brought on by eczema. A new book has ... who they are and to find relief from the condition ...
Breaking Medicine News(10 mins):Health News:INDIGO Offers Human Estrogen-related Receptor Gamma Assay System 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... XP Electroanatomical Mapping System combines the legendary ... operating ease of Windows* software. It ... powerful new tools that enhance your clinical ... you into the future of EP. ...
... pulse generators are meeting the clinical ... electrophysiologists and anesthesiologists. And, they are ... expect from Medtronic.,Effective pacing with the ... polarity for quick battery changes. ...
... is a unique left ventricular assist device that ... is being used in a small group of ... part of an FDA-approved Feasibility Study. The patient ... external power source for minutes or hours. The ...
... introduced the world's first minimally-invasive epicardial lead ... Lead Implant Tool, which has been cleared ... expand the options available to implanting physicians ... on the heart during pacemaker implants. The ...
Medicine Products: